Loading...
Motilal Oswal S&P BSE Healthcare ETF
EquitySector - HealthcareVery High Risk
NAV (21-Nov-24)
₹42.810.11%1D
Returns (Since Inception)
31.01%
Rated ★4.5+ on 
Fund Overview
Fund Size
₹29 Cr
Expense Ratio
0.22%
ISIN
INF247L01BB1
Minimum SIP
-
Exit Load
-
Inception Date
29 Jul 2022
About this fund
Motilal Oswal S&P BSE Healthcare ETF is a Sector - Healthcare mutual fund schemes offered by Motilal Oswal Mutual Fund. This fund has been in existence for 2 years, 3 months and 24 days, having been launched on 29-Jul-22.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹42.81, Assets Under Management (AUM) of 28.64 Crores, and an expense ratio of 0.22%.
As of 21-Nov-24, it has a Net Asset Value (NAV) of ₹42.81, Assets Under Management (AUM) of 28.64 Crores, and an expense ratio of 0.22%.
- Motilal Oswal S&P BSE Healthcare ETF has given a CAGR return of 31.01% since inception.
- The fund's asset allocation comprises around 99.83% in equities, 0.00% in debts, and 0.17% in cash & cash equivalents.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+42.98%
+41.83% (Cat Avg.)
Since Inception
+31.01%
— (Cat Avg.)
Portfolio Summaryas of 31st October 2024
| Equity | ₹28.59 Cr | 99.83% |
| Others | ₹0.05 Cr | 0.17% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹4.41 Cr | 15.41% |
| Cipla Ltd | Equity | ₹1.91 Cr | 6.68% |
| Dr Reddy's Laboratories Ltd | Equity | ₹1.72 Cr | 5.99% |
| Divi's Laboratories Ltd | Equity | ₹1.66 Cr | 5.80% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.66 Cr | 5.80% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹1.56 Cr | 5.45% |
| Lupin Ltd | Equity | ₹1.17 Cr | 4.08% |
| Aurobindo Pharma Ltd | Equity | ₹0.87 Cr | 3.03% |
| Fortis Healthcare Ltd | Equity | ₹0.72 Cr | 2.52% |
| Alkem Laboratories Ltd | Equity | ₹0.67 Cr | 2.35% |
| Torrent Pharmaceuticals Ltd | Equity | ₹0.65 Cr | 2.26% |
| Mankind Pharma Ltd | Equity | ₹0.59 Cr | 2.06% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹0.56 Cr | 1.95% |
| Zydus Lifesciences Ltd | Equity | ₹0.56 Cr | 1.94% |
| Ipca Laboratories Ltd | Equity | ₹0.47 Cr | 1.65% |
| Laurus Labs Ltd | Equity | ₹0.43 Cr | 1.49% |
| Suven Pharmaceuticals Ltd | Equity | ₹0.37 Cr | 1.29% |
| Piramal Pharma Ltd | Equity | ₹0.36 Cr | 1.26% |
| Syngene International Ltd | Equity | ₹0.34 Cr | 1.20% |
| Abbott India Ltd | Equity | ₹0.34 Cr | 1.18% |
| Biocon Ltd | Equity | ₹0.31 Cr | 1.08% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹0.31 Cr | 1.08% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹0.29 Cr | 1.03% |
| Gland Pharma Ltd | Equity | ₹0.29 Cr | 1.01% |
| Ajanta Pharma Ltd | Equity | ₹0.29 Cr | 1.01% |
| Natco Pharma Ltd | Equity | ₹0.28 Cr | 0.97% |
| Neuland Laboratories Limited | Equity | ₹0.28 Cr | 0.97% |
| Dr. Lal PathLabs Ltd | Equity | ₹0.25 Cr | 0.88% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹0.24 Cr | 0.85% |
| Concord Biotech Ltd | Equity | ₹0.24 Cr | 0.83% |
| Strides Pharma Science Ltd | Equity | ₹0.23 Cr | 0.82% |
| Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹0.22 Cr | 0.77% |
| Poly Medicure Ltd | Equity | ₹0.22 Cr | 0.76% |
| Global Health Ltd | Equity | ₹0.2 Cr | 0.71% |
| Jubilant Pharmova Ltd | Equity | ₹0.2 Cr | 0.70% |
| Wockhardt Ltd | Equity | ₹0.2 Cr | 0.69% |
| Narayana Hrudayalaya Ltd | Equity | ₹0.19 Cr | 0.66% |
| Granules India Ltd | Equity | ₹0.18 Cr | 0.64% |
| Rainbow Childrens Medicare Ltd | Equity | ₹0.18 Cr | 0.63% |
| Pfizer Ltd | Equity | ₹0.17 Cr | 0.60% |
| Eris Lifesciences Ltd Registered Shs | Equity | ₹0.14 Cr | 0.49% |
| Alembic Pharmaceuticals Ltd | Equity | ₹0.14 Cr | 0.48% |
| Sanofi India Ltd | Equity | ₹0.13 Cr | 0.47% |
| Marksans Pharma Ltd | Equity | ₹0.13 Cr | 0.46% |
| Metropolis Healthcare Ltd | Equity | ₹0.12 Cr | 0.42% |
| Jupiter Life Line Hospitals Ltd | Equity | ₹0.11 Cr | 0.39% |
| AstraZeneca Pharma India Ltd | Equity | ₹0.11 Cr | 0.37% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹0.1 Cr | 0.36% |
| Ami Organics Ltd | Equity | ₹0.1 Cr | 0.36% |
| Shilpa Medicare Ltd | Equity | ₹0.1 Cr | 0.35% |
| Procter & Gamble Health Ltd | Equity | ₹0.09 Cr | 0.32% |
| Caplin Point Laboratories Ltd | Equity | ₹0.09 Cr | 0.32% |
| Glenmark Life Sciences Ltd | Equity | ₹0.07 Cr | 0.25% |
| Aarti Pharmalabs Ltd | Equity | ₹0.07 Cr | 0.24% |
| Morepen Laboratories Ltd | Equity | ₹0.06 Cr | 0.21% |
| FDC Ltd | Equity | ₹0.06 Cr | 0.21% |
| Kovai Medical Center & Hospital Ltd | Equity | ₹0.06 Cr | 0.20% |
| Indegene Ltd | Equity | ₹0.06 Cr | 0.20% |
| Advanced Enzyme Technologies Ltd | Equity | ₹0.05 Cr | 0.18% |
| Net Receivables / (Payables) | Cash | ₹0.05 Cr | 0.17% |
| Orchid Pharma Ltd | Equity | ₹0.05 Cr | 0.17% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹0.05 Cr | 0.17% |
| Sequent Scientific Ltd | Equity | ₹0.05 Cr | 0.16% |
| Solara Active Pharma Sciences Ltd Ordinary Shares | Equity | ₹0.05 Cr | 0.16% |
| Yatharth Hospital and Trauma Care Services Ltd | Equity | ₹0.04 Cr | 0.14% |
| HealthCare Global Enterprises Ltd | Equity | ₹0.04 Cr | 0.14% |
| Indraprastha Medical Corp Ltd | Equity | ₹0.04 Cr | 0.14% |
| Krsnaa Diagnostics Ltd | Equity | ₹0.04 Cr | 0.13% |
| Unichem Laboratories Ltd | Equity | ₹0.04 Cr | 0.13% |
| Aarti Drugs Ltd | Equity | ₹0.04 Cr | 0.13% |
| Supriya Lifescience Ltd | Equity | ₹0.04 Cr | 0.12% |
| Hikal Ltd | Equity | ₹0.03 Cr | 0.11% |
| Thyrocare Technologies Ltd | Equity | ₹0.03 Cr | 0.11% |
| Dishman Carbogen Amics Ltd | Equity | ₹0.03 Cr | 0.10% |
| Innova Captab Ltd | Equity | ₹0.03 Cr | 0.09% |
| Gufic Biosciences Ltd | Equity | ₹0.03 Cr | 0.09% |
| Blue Jet Healthcare Ltd | Equity | ₹0.03 Cr | 0.09% |
| Indoco Remedies Ltd | Equity | ₹0.03 Cr | 0.09% |
| RPG Life Sciences Ltd | Equity | ₹0.02 Cr | 0.08% |
| Syncom Formulation (India) Ltd | Equity | ₹0.02 Cr | 0.07% |
| IOL Chemicals And Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.07% |
| Hester Biosciences Ltd | Equity | ₹0.02 Cr | 0.07% |
| Gujarat Themis Biosyn Ltd | Equity | ₹0.02 Cr | 0.07% |
| SMS Pharmaceuticals Ltd | Equity | ₹0.02 Cr | 0.07% |
| Windlas Biotech Ltd | Equity | ₹0.02 Cr | 0.07% |
| Bliss GVS Pharma Ltd | Equity | ₹0.02 Cr | 0.06% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹0.02 Cr | 0.06% |
| Suven Life Sciences Ltd | Equity | ₹0.02 Cr | 0.06% |
| Sigachi Industries Ltd | Equity | ₹0.02 Cr | 0.06% |
| Kopran Ltd | Equity | ₹0.02 Cr | 0.06% |
| Themis Medicare Ltd | Equity | ₹0.02 Cr | 0.06% |
| Novartis India Ltd | Equity | ₹0.02 Cr | 0.05% |
| Shalby Ltd | Equity | ₹0.01 Cr | 0.05% |
| Lincoln Pharmaceuticals Ltd | Equity | ₹0.01 Cr | 0.05% |
| Tarsons Products Ltd | Equity | ₹0.01 Cr | 0.05% |
| GPT Healthcare Ltd | Equity | ₹0.01 Cr | 0.04% |
| Vimta Labs Ltd | Equity | ₹0.01 Cr | 0.03% |
| NGL Fine-Chem Ltd | Equity | ₹0.01 Cr | 0.03% |
| KMC Speciality Hospitals (India) Ltd | Equity | ₹0.01 Cr | 0.02% |
| Sastasundar Ventures Ltd | Equity | ₹0.01 Cr | 0.02% |
Allocation By Market Cap (Equity)
Large Cap Stocks
45.59%
Mid Cap Stocks
28.41%
Small Cap Stocks
24.86%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹28.16 Cr | 98.32% |
| Basic Materials | ₹0.15 Cr | 0.54% |
Risk & Performance Ratios
Standard Deviation
This fund
--
Cat. avg.
15.67%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.91
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Fund Managers
Additional Scheme Detailsas of 31st October 2024
ISIN INF247L01BB1 | Expense Ratio 0.22% | Exit Load - | Fund Size ₹29 Cr | Age 2 years 3 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Sector - Healthcare Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹28.64 Cr | 43.0% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹881.52 Cr | 37.2% |
| Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹881.52 Cr | 35.4% |
| Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹40.84 Cr | 37.9% |
| ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹208.21 Cr | 45.8% |
| ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹208.21 Cr | 43.1% |
| Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2770.21 Cr | 38.2% |
| Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2770.21 Cr | 36.2% |
| Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹852.28 Cr | 36.6% |
| Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.81 Cr | 37.0% |
About the AMC
Motilal Oswal Mutual Fund
Total AUM
₹78,015 Cr
Address
Motilal Oswal Tower, Mumbai, 400 025
Other Funds by Motilal Oswal Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Unlock Expert Insights!
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Motilal Oswal S&P BSE Healthcare ETF?
The NAV of Motilal Oswal S&P BSE Healthcare ETF, as of 21-Nov-2024, is ₹42.81.
What is the portfolio composition of Motilal Oswal S&P BSE Healthcare ETF?
The fund's allocation of assets is distributed as 99.83% in equities, 0.00% in bonds, and 0.17% in cash and cash equivalents.
Who manages the Motilal Oswal S&P BSE Healthcare ETF?
The fund managers responsible for Motilal Oswal S&P BSE Healthcare ETF are:-
- Swapnil Mayekar
- Rakesh Shetty
- Dishant Mehta
Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
©2021-2024 Dezerv. All Rights Reserved
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.